> ## Content Index > Fetch the complete content index at: https://7.cr/llms.txt > Use this file to discover other available public pages before exploring further. # Oncology and Rare Disease Trials: Why Rising Complexity Is Reshaping Site Selection - URL: https://7.cr/oncology-rare-disease-trials-complexity-reshaping-site-selection/ - Published: 2026-04-02T22:46:25.000Z - Updated: 2026-08-14T19:13:24.000Z - Description: A Seven Health look at why oncology and rare disease complexity is reshaping what sponsors look for in a clinical trial site partner. - Author: Kevin Sindhu - Tags: Oncology & Rare Disease, Clinical Research & CRO, Site Feasibility, #Import 2026-08-14 12:00 ## Complexity Has Become the Defining Feature of the Modern Trial Pipeline Clinical trial protocols have grown measurably more complex over the past decade, and nowhere is that complexity more concentrated than in **oncology and rare disease research**, which together now account for **more than half of all drugs currently in active development**. For site networks and the business development teams supporting them, including Seven Health and 7 Consult's work with embedded research sites, this concentration of complexity is fundamentally reshaping what sponsors look for in a feasibility partner, and which sites are positioned to compete for this rapidly growing share of the overall trial pipeline. ## Why Rare Disease and Oncology Trials Are Structurally Different Rare disease and oncology protocols differ from more traditional therapeutic area trials in ways that directly affect site selection and operational demands. Rare disease studies, by definition, draw from an extremely narrow, often geographically dispersed patient population, meaning a single site's local catchment area is frequently insufficient to support meaningful enrollment on its own. Oncology trials increasingly incorporate biomarker-driven, precision medicine designs, where a patient must match not just a broad diagnosis but a specific genetic or molecular profile, further narrowing the eligible population within any given site's reach. This combination, narrow eligible populations and increasingly specific biomarker or genetic matching criteria, has made **patient identification and recruitment the single greatest bottleneck** in oncology and rare disease clinical program success, more so than almost any other operational factor sponsors manage. ## What Sponsors Are Looking For in Oncology and Rare Disease Feasibility Given this recruitment bottleneck, sponsors evaluating site feasibility for oncology and rare disease studies weight a somewhat different set of factors than for more common indications: - **Genetic and molecular testing infrastructure**, since biomarker-driven oncology trials increasingly require sites to have reliable access to the specific testing needed to confirm patient eligibility, whether performed on-site or through an established reference lab relationship - **Multi-site or network-level population reach**, recognizing that a single site's local population is often insufficient on its own, making networks with a broader combined catchment area, or strong referral relationships with other institutions, meaningfully more attractive - **Rare disease patient navigator capability**, a specialized recruitment and retention function increasingly used specifically to help identify and support the small, often geographically dispersed patient populations these studies require - **Long-term retention infrastructure**, since many oncology and rare disease protocols run considerably longer than typical trials, with extended follow-up periods that demand sustained coordinator relationship management with a small, often medically complex patient population ## The Referral Network Advantage For embedded research networks, particularly those built inside a larger health system with connections across primary care, specialty care, and community clinics, the referral pathway becomes a particularly powerful asset in oncology and rare disease recruitment. A patient meeting narrow biomarker or rare disease diagnostic criteria is far more likely to be identified through a physician who already knows and refers to the research team than through broad community advertising, which tends to perform poorly against these narrow, clinically specific eligibility criteria. Networks that build and actively maintain strong internal referral pathways between specialty physicians and the research team materially outperform networks relying primarily on advertising-based recruitment for these complex indications. ## Data and Technology Requirements Are Higher Too Beyond patient identification, oncology and rare disease trials frequently carry more demanding data and technology requirements than more traditional protocols. Biomarker-driven studies often require sophisticated data integration between genetic testing results, imaging data, and standard clinical trial data capture, while rare disease natural history studies increasingly incorporate real-world evidence and long-term registry data alongside interventional trial data. Sites and networks with mature data infrastructure, of the kind described in Seven Health's broader work on real-world evidence and AI-assisted recruitment readiness, are positioned to support this complexity more credibly than sites relying on more basic, siloed data systems. ## The Business Case for Building Oncology and Rare Disease Capability Given that these two therapeutic areas now represent the majority of the active drug development pipeline, and given the sustained funding recovery described elsewhere driving continued investment specifically into oncology and other complex indications, building genuine operational capability in this space represents one of the more durable, long-term business development opportunities available to a growing site network. This isn't a short-term trend tied to a specific drug class, the way the current GLP-1 and metabolic disease wave might eventually mature, but rather a structural feature of where drug development as a whole is headed over the coming decade. ## A Practical Checklist for Building Oncology and Rare Disease Capability Networks looking to build genuine, durable capability in this space can prioritize a few concrete steps: map existing referral relationships with specialty physicians, particularly oncology and genetics, and invest deliberately in strengthening those pathways rather than assuming they'll develop organically; establish a reliable reference laboratory relationship capable of turning around biomarker and genetic testing within the timelines complex protocols require; consider whether a rare disease patient navigator role, distinct from a standard clinical research coordinator, would meaningfully strengthen the network's recruitment and retention capability for these specific indications; and build the long-term retention infrastructure, including sustained coordinator relationship continuity, that extended oncology and rare disease follow-up periods specifically demand. ## Frequently Asked Questions on Oncology and Rare Disease Trial Complexity **Does a site need on-site genetic testing capability to compete for biomarker-driven oncology studies?** Not necessarily, though it strengthens a feasibility response. Many sites compete effectively through a strong, established relationship with a reference laboratory capable of turning around the required testing within the timeline a study protocol requires. **How important is a rare disease patient navigator role compared to a standard clinical research coordinator?** Increasingly important for rare disease-focused programs specifically, since patient navigators bring a specialized skill set around identifying and supporting a very narrow, often geographically dispersed and medically complex patient population that differs meaningfully from standard coordinator responsibilities. **Is oncology and rare disease trial work accessible to mid-size embedded networks, or primarily the domain of large academic cancer centers?** Increasingly accessible to well-positioned mid-size networks, particularly those with strong specialty referral relationships and a demonstrated ability to support the data and testing infrastructure these studies require, though large academic centers retain a natural advantage for the most complex, earliest-phase oncology work. ## Conclusion Oncology and rare disease research now represent the structural center of gravity in clinical drug development, and the patient identification and recruitment complexity inherent to these therapeutic areas is reshaping what sponsors look for in a site partner. Seven Health and 7 Consult see this as one of the clearest, most durable opportunities available to embedded research networks with strong specialty referral relationships and the data infrastructure maturity to support increasingly complex, biomarker-driven protocol requirements.